BioNTech SE
FSX: 22UA.F0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Frankfurt Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ugur Sahin
- Employees
- 6,772
- Headquarters
- Mainz, Germany
- IPO year
- 2019
- Market cap
- €20.1B
- Website
- https://www.biontech.de
Loading 22UA…
Loading profile data…Frequently asked questions about 22UA
What does BioNTech SE (22UA.F) do?
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
Where does 22UA.F trade?
BioNTech SE (22UA.F) trades on the Frankfurt Stock Exchange.
What sector is 22UA.F in?
BioNTech SE (22UA.F) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BioNTech SE?
Ugur Sahin is the chief executive officer of BioNTech SE (22UA.F).
Where is BioNTech SE headquartered?
BioNTech SE is headquartered in Germany.
Does 22UA.F pay a dividend?
BioNTech SE (22UA.F) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 22UA.F go public?
BioNTech SE (22UA.F) completed its initial public offering in 2019.